Pharmaceuticals

Bispecific Antibody Innovations Accelerating Development in the Cancer Biologics Market

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cancer biologics Market Over The Period 2026–2030?

The cancer biologics market size has demonstrated significant growth in recent years. It is anticipated to increase from $129.05 billion in 2025 to $140.88 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.2%. This expansion during the historical period is primarily due to several factors: a rising global prevalence of cancer, an increasing demand for sophisticated cancer therapies, intensified oncology research initiatives, the inherent limitations of conventional chemotherapy, and the broadening network of hospital-based cancer treatment centers.

The cancer biologics market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $203.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is primarily driven by progress in cell and gene therapy platforms, a rise in approvals for new biologics, the expansion of personalized oncology therapies, increased investment in research and development for cancer biologics, and an increase in biologics manufacturing capabilities. Key trends expected during this period involve the greater adoption of immunotherapy and targeted biologic treatments, a growing application of monoclonal antibodies in oncology, the development of cell and gene therapy-based approaches for cancer, an increase in cancer vaccine development initiatives, and an enhanced emphasis on combination biologic therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Drivers Are Expected To Influence The Cancer biologics Market During The Forecast Period?

The increasing incidence of chronic diseases stands as a primary catalyst for the expansion of the cancer biologics market. Chronic disorders, defined as long-lasting conditions that negatively impact the health of individuals, count cancer among their most prevalent forms. Commonly identified cancers encompass breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, reports published in February 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicate that a growing number of people in America manage multiple chronic conditions, with 42% having two or more and 12% experiencing five or more. Thus, the rising prevalence of chronic diseases is expected to stimulate the cancer biologics market growth in the coming years.

How Is The Cancer biologics Market Divided Into Its Major Segments?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

How Are Trends Transforming The Cancer biologics Market Landscape?

Leading companies in the cancer biologics market are prioritizing the development of innovative treatments, such as bispecific antibodies and biomarker-guided biologics, to enhance treatment efficacy and more effectively target specific cancer cells. Bispecific antibodies are an advanced biologic therapy designed to bind to two separate epitopes or targets concurrently, while biomarker-guided biologics are specifically engineered to target tumor cells identified by particular molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a Dublin-based global biopharmaceutical company, received acceleration approval from the U.S. Food & Drug Administration (FDA) for Ziihera (zanidatamab hrii) for adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the first and only dual HER2 targeted bispecific antibody for this indication, thereby extending the application of HER2-targeted biologic therapy into a new tumor type beyond its classical indications.

Who Are The Prominent Organizations Shaping The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Read the full cancer biologics market report here:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Region Is Forecast To Lead The Cancer biologics Market In Terms Of Market Size?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795